Taíse Lima Cerqueira De-Oliveira

Taíse Lima Cerqueira De-Oliveira

Auto-generated profile, based on publicly available information

Taíse Lima Cerqueira De-Oliveira

Federal University of Bahia, Department of Biorregulation, Health & Sciences Institute

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2024 in Brazilian Journal of Oncology
Verified
Journal Article
Open access
ATAna Clara Oliveira Tosta Telles
Ana Clara Oliveira Tosta Telles
GMGabriel Jeferson Rodríguez Machado
Gabriel Jeferson Rodríguez Machado
JVJuliana Lima Von-Ammon
Juliana Lima Von-Ammon
RDRafael Reis Campos Da-Matta
Rafael Reis Campos Da-Matta
TDTaíse Lima Cerqueira De-Oliveira
Taíse Lima Cerqueira De-Oliveira
HRHELTON RAMOS
HELTON RAMOS
Introduction: Pan-TRK immunohistochemistry staining can assess the protein expression from NTRK gene fusions. A little is known about its utility in differentiated thyroid cancer samples from children, adolescents, and young adults patients. Objective:Investigate pan-TRKimmunohistochemistry sensitivity and specificity in differentiated thyroid cancer samples from children, adolescents, and young adults patients. Methods: Tumor samples obtained from 79 children, adolescents, and young adults patients (age <21 years) diagnosed with differentiated thyroid cancer between January, 2010 and January, 2021 were retrospectively recruited from four health centers from state of Bahia e Paraíba, Brazil. NTRK gene fusion testing of all archival FFPE tumor samples: pan-TRK immunohistochemistry staining for TRKA, TRKB and TRKC protein expression were performed and then analyzed with RNA-based nextgeneration sequencing assay to confirm immunohistochemistry pan-TRK result and elucidate fusion partner. Results: Pan-TRK immunohistochemistry: 3 of 79 cases had positive pan-TRK expression: next-generation sequencing; 4 were identified with NTRK gene fusion, pan-TRK immunohistochemistry was negative in all 4 NTRK next-generation sequencing-positive cases. 25 of 79 NTRK next-generation sequencing-negative control cases had concordant negative pan-TRK immunohistochemistry results. Therefore, our rate of false positive pan-TRK immunohistochemistry results was 3/25 (12%). The overall results for pan-TRK immunohistochemistry in our cohort of next-generation sequencing-negative cases was: (i) sensitivity (0%), (ii) specificity (96%), (iii) positive predictive value (94.7%), (iv) negative predictive value (91%). Conclusion: Pan-TRK immunohistochemistry was not a tissue-efficient screen for NTRK fusions in differentiated thyroid cancer from children, adolescents, and young adults patients. This is the largest cohort of from children, adolescents, and young adults differentiated thyroid cancer cases stained with pan-TRK immunohistochemistry, and it is the first to detail the sensitivity and specificity of pan-TRK immunohistochemistry regarding the data obtained by targeted RNA-based next-generation sequencing panel in differentiated thyroid cancer.